Raras
Buscar doenças, sintomas, genes...
Ependimoma RELA fusão-positivo
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

O fator de transcrição p65, também conhecido como subunidade p65 do fator nuclear NF-kappa-B, é uma proteína que em humanos é codificada pelo gene RELA.

Publicações científicas
15 artigos
Último publicado: 2022 Dec

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adolescent
+ adult, childhood, infancy
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D43.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa4desde 2022
Total histórico15PubMed
Últimos 10 anos15publicações
Pico20204 papers
Linha do tempo
2022Hoje · 2026🧪 2018Primeiro ensaio clínico📈 2020Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição.

RELATranscription factor p65Part of a fusion gene inAltamente restrito
FUNÇÃO

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (10)
TAK1-dependent IKK and NF-kappa-B activation TRAF6 mediated NF-kB activationRIP-mediated NFkB activation via ZBP1DEx/H-box helicases activate type I IFN and inflammatory cytokines production IkBA variant leads to EDA-ID
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
113.1 TPM
Útero
107.8 TPM
Aorta
106.1 TPM
Nervo tibial
99.7 TPM
Cervix Endocervix
98.3 TPM
OUTRAS DOENÇAS (3)
mucocutaneous ulceration, chroniccombined immunodeficiency due to RELA haploinsufficiencyRELA fusion-positive ependymoma
HGNC:9955UniProt:Q04206
ZFTAZinc finger translocation-associated proteinPart of a fusion gene inTolerante
LOCALIZAÇÃO

OUTRAS DOENÇAS (2)
ependymomaRELA fusion-positive ependymoma
HGNC:28449UniProt:C9JLR9

Variantes genéticas (ClinVar)

69 variantes patogênicas registradas no ClinVar.

🧬 RELA: NM_021975.4(RELA):c.31del (p.Ala11fs) ()
🧬 RELA: NM_021975.4(RELA):c.19del (p.Leu7fs) ()
🧬 RELA: NM_021975.4(RELA):c.350dup (p.Ile118fs) ()
🧬 RELA: NM_021975.4(RELA):c.1288C>T (p.Gln430Ter) ()
🧬 RELA: NM_021975.4(RELA):c.1044dup (p.Tyr349fs) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
1Fase 11
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Ependimoma RELA fusão-positivo

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥉Melhor nível de evidência: Relato de caso
Timeline de publicações
15 papers (10 anos)
#1

Supratentorial ependymoma, zinc finger translocation-associated fusion positive, with extensive synaptophysin immunoreactivity arising from malignant transformation of clear cell ependymoma: A case report.

Surgical neurology international2022

We describe a case of a supratentorial ependymoma, zinc finger translocation-associated (ZFTA) fusion positive with extensive synaptophysin immunoreactivity arising from malignant transformation of an ependymoma with clear cell features in a patient with long-term follow-up. A 55-year-old woman presented with seizures and ataxia 15 years after an initial resection of a clear cell ependymoma, Grade 2. Imaging demonstrated an enhancing right paracentral mass and the patient underwent biopsy and resection. Microscopic analysis showed regions of the tumor with morphological and immunohistochemical features typical of ependymoma, including perivascular pseudorosettes and focal dot- like epithelial membrane antigen positivity, as well as high-grade features. In addition, the neoplasm contained large nodular regions of clear cells exhibiting extensive synaptophysin immunoreactivity, suggestive of neural differentiation, and only focally positive immunoreactivity for glial markers. Electron microscopy showed poorly formed and ill-defined junctional complexes, but no cilia, microvilli, or dense granules were seen. Molecular profiling revealed the presence of a fusion between ZFTA (previously known as C11orf95) and RELA fusion. We report a case of extensive synaptophysin immunoreactivity in a ZFTA-RELA fusion-positive ependymoma that had undergone malignant transformation from a clear cell ependymoma and has long-term follow-up, contributing to the assessment of prognostic significance of synaptophysin immunoreactivity in supratentorial ependymoma, ZFTA fusion positive.

#2

Ependymomas.

Pathologica2022 Dec

Ependymal neoplasms are a heterogenous group of neoplasms arising from the progenitors of the cells lining the ventricular system and the spinal central canal. During the last few years, significant novel data concerning oncogenesis, molecular characteristics and clinical correlations of these tumours have been collected, with a strong relevance for their pathological classification. The recently published 5th edition of WHO Classification of Central Nervous System Tumours integrates this novel knowledge and represents a substantial update compared to the previous edition. Concerning supratentorial ependymomas, the previous RELA fusion-positive ependymoma has been renamed into ZFTA fusion-positive and the novel YAP1 fusion-positive ependymoma subtype has been added. Posterior fossa ependymomas should now be allocated either to the Type A or Type B subtypes based on molecular profiling or using the H3 K27me3 immunohistochemical surrogate. Regarding spinal ependymomas, a novel subtype has been added based on a distinctive molecular trait, presence of MYCN amplification, and on the unfavourable outcome. Finally, myxopapillary ependymoma is now classified as a grade 2 tumour in accordance with its overall prognosis which mirrors that of conventional spinal ependymomas. The aim of this review is to present these changes and summarize the current diagnostic framework of ependymal tumours, according to the most recent updates.

#3

Supratentorial extra-axial RELA fusion-positive ependymoma misdiagnosed as meningioma by intraoperative histological and cytological examinations: a case report.

Journal of medical case reports2022 Aug 20

Dura-attached supratentorial extra-axial ependymoma is a very rare type of tumor, with only nine reported cases. Preoperative diagnosis of dura-attached supratentorial extra-axial ependymoma is difficult and often radiologically misdiagnosed as a meningioma. We report a case of dura-attached supratentorial extra-axial ependymoma that was misdiagnosed using intraoperative histological and cytological examinations. A 26-year-old Japanese man with headache and nausea was referred to our medical facility. Magnetic resonance imaging revealed a cystic mass of 70 × 53 × 57 mm in the left temporoparietal lobe. A peritumoral band with hyperintensity on T2-weighted imaging was observed at the periphery of the lesion, suggesting an extra-axial lesion with no apparent connection to the ventricle. A dural tail sign was also noted on the gadolinium-enhanced T1-weighted image. Preoperative clinical diagnosis was meningioma. Proliferated tumor cells in sheets with intermingled branching vessels were observed in the frozen tissue. Perivascular rosettes were inconspicuous, and the tumor cells had rhabdoid cytoplasm. The tumor was intraoperatively diagnosed as a meningioma, suspected to be a rhabdoid meningioma. Perivascular rosettes were evident in the formalin-fixed paraffin-embedded tissues, suggesting ependymoma. The tumor cells had eosinophilic cytoplasm without a rhabdoid appearance. Anaplastic features, such as high tumor cellularity, increased mitotic activity, microvascular proliferation, and necrosis, were observed. Ependymal differentiation was confirmed on the basis of ultrastructural analysis. Molecular analysis detected C11orf95-RELA fusion gene. The final diagnosis was RELA fusion-positive ependymoma, World Health Organization grade III. Owing to its unusual location, dura-attached supratentorial extra-axial ependymomas are frequently misdiagnosed as meningiomas. Neuropathologists should take great precaution in intraoperatively diagnosing this rare subtype of ependymoma to avoid misdiagnosis of the lesion as other common dura-attached tumors.

#4

Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features.

Brain tumor pathology2021 Jan

C11orf95-RELA fusion or, less frequently, YAP1 fusion is recurrently detected in most cases of supratentorial ependymoma. Other fusions have rarely been reported in some cases of supratentorial ependymoma, and little is known about their pathological or clinical features. Here, we present a case of supratentorial ependymoma with unusual pathological findings and C11orf95-MAML2 fusion. A 23-year-old man was admitted to our hospital because of headache and vomiting. Magnetic resonance imaging revealed a cystic lesion in the right frontal lobe, and gross total resection of the tumor was performed. Pathologically, the tumor was mainly composed of typical ependymal lesions with perivascular pseudorosettes and contained some atypical lesions, with granular and ganglion cell features. The tumor was diagnosed as anaplastic ependymoma, which was classified as grade III on the World Health Organization scale, and found to be RELA fusion-positive in the DNA methylation analysis. However, the tumor was negative for C11orf95-RELA fusion, and RNA sequencing detected C11orf95-MAML2 fusion. The patient has not received adjuvant therapy and has remained alive without any evidence of disease for 30 months, suggesting that the prognosis might be better than that of typical C11orf95-RELA fusion-positive ependymoma.

#5

RELA Fusion-Positive Ependymoma in a Child with Down Syndrome: A Case Report.

Pediatric neurosurgery2021

Down syndrome (DS) is the most common multiple malformation syndrome in humans and is associated with an increased risk of childhood malignancy, particularly leukemia. Incidence of brain tumors in patients with DS is limited to sporadic cases. We report the first case of a RELA fusion-positive ependymoma in a 3-year-old boy with DS. Imaging prompted by new left-sided hemiparesis demonstrated an 8-cm hemorrhagic right temporal-parietal mass. Subsequent image-complete resection confirmed a RELA fusion-positive anaplastic ependymoma with 90% OLIG2 staining. Postoperatively, the patient, unfortunately, experienced fatal recurrence and drop metastases with leptomeningeal involvement. To our knowledge, this is the first reported case of a confirmed RELA fusion-positive ependymoma in a child with DS. We discuss this finding in the context of intracranial tumors in children with DS, as well as the finding of 90% positive OLIG2 expression and its potential as a prognostic marker.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC7 artigos no totalmostrando 14

2022

Supratentorial extra-axial RELA fusion-positive ependymoma misdiagnosed as meningioma by intraoperative histological and cytological examinations: a case report.

Journal of medical case reports
2022

Supratentorial ependymoma, zinc finger translocation-associated fusion positive, with extensive synaptophysin immunoreactivity arising from malignant transformation of clear cell ependymoma: A case report.

Surgical neurology international
2021

RELA Fusion-Positive Ependymoma in a Child with Down Syndrome: A Case Report.

Pediatric neurosurgery
2021

Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features.

Brain tumor pathology
2020

Cortically based cystic supratentorial RELA fusion-positive ependymoma: a case report with unusual presentation and appearance and review of literature.

Radiology case reports
2020

RELA fusion-positive ependymoma accompanied by extensive desmoplasia: a case report.

Brain tumor pathology
2020

L1CAM High Expression Associates with Poor Prognosis in Glioma but Does Not Correlate with C11orf95-RELA Fusion.

BioMed research international
2020

In vitro benchmarking of NF-κB inhibitors.

European journal of pharmacology
2018

Preoperative and intraoperative perfusion magnetic resonance imaging in a RELA fusion-positive anaplastic ependymoma: A case report.

Surgical neurology international
2018

DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.

Neuro-oncology
2017

A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016.

Journal of neurosciences in rural practice
2018

WHO 2016 Classification of gliomas.

Neuropathology and applied neurobiology
2017

The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.

Neurologia medico-chirurgica
2016

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Acta neuropathologica

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Ependimoma RELA fusão-positivo.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Ependimoma RELA fusão-positivo

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Supratentorial ependymoma, zinc finger translocation-associated fusion positive, with extensive synaptophysin immunoreactivity arising from malignant transformation of clear cell ependymoma: A case report.
    Surgical neurology international· 2022· PMID 35509570mais citado
  2. Ependymomas.
    Pathologica· 2022· PMID 36534422mais citado
  3. Supratentorial extra-axial RELA fusion-positive ependymoma misdiagnosed as meningioma by intraoperative histological and cytological examinations: a case report.
    Journal of medical case reports· 2022· PMID 35986385mais citado
  4. Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features.
    Brain tumor pathology· 2021· PMID 33221956mais citado
  5. RELA Fusion-Positive Ependymoma in a Child with Down Syndrome: A Case Report.
    Pediatric neurosurgery· 2021· PMID 33690230mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:530792(Orphanet)
  2. MONDO:0033980(MONDO)
  3. GARD:22210(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Ependimoma RELA fusão-positivo
Compêndio · Raras BR

Ependimoma RELA fusão-positivo

ORPHA:530792 · MONDO:0033980
Prevalência
Unknown
CID-10
D43.0 · Neoplasia de comportamento incerto ou desconhecido do encéfalo, supratentorial
Início
Adolescent, Adult, Childhood, Infancy
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C4289581
Repurposing
1 candidato
carmustineDNA alkylating agent|DNA inhibitor
EuropePMC
Papers 10a
Evidência
🥉 Relato de caso
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades